The cell cycle constitutes a series of events required for cell division, controlled by cyclin-dependent kinases (CDKs) and their inhibitors \[[@B3][@B14]\]. *Cdkn2a* (cyclin-dependent kinase inhibitor 2a) is a cell cycle regulating gene encoding alternate proteins, p16^Ink4a^ and p19^Arf^, that arrest the G1 phase through CDK4/6 inhibition \[[@B10][@B12]\]. As they are tumor suppressors, p16^Ink4a^ and p19^Arf^ can be targeted for treatment of various cancers, including melanoma, cervical, and esophageal cancers \[[@B4][@B13][@B22][@B30][@B32]\]. p27^Kip1^ is another type of CDK inhibitor which suppresses CDK2, a CDK required for S phase entry \[[@B23]\]. Orchestration of these kinases and their inhibitors controls the cell cycle; therefore, mutations in these proteins can cause severe disease \[[@B16][@B25][@B33]\]. For these reasons, knockout (KO) mouse models for these genes have been generated and extensively studied for almost three decades \[[@B2][@B26]\].

The use of engineered nucleases, such as transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9), can tremendously reduce the time and cost required for mouse model production \[[@B11][@B28][@B29]\]. TALENs consist of transcription activator-like (TAL) effectors fused with a FokI cleavage domain \[[@B9]\]. Each TAL effector can be engineered to recognize specific DNA sequences by customizing the amino acids at the 12^th^ and 13^th^ position of each \~34 amino acid repeat in the protein\'s variable region \[[@B6]\]. CRISPR/Cas9 is a ribonucleoprotein complex, containing a single guide RNA (sgRNA) with a targeting sequence and a Cas9 protein which recognizes a protospacer adjacent motif and cleaves the target site \[[@B24]\].

To better understand the mechanisms by which CDK inhibitors influence tumor progression, and to permit study without any intervening patent or authority, we established KO mouse models for p16^Ink4a^, p19^Arf^, and p27^Kip1^. While previous mouse models were generated using homologous recombination in embryonic stem (ES) cells \[[@B17][@B26]\], ours utilized TALEN- and CRISPR/Cas9 to induce indels via non-homologous end joining repair. These nuclease-mediated approaches permitted generation of KOs without the addition of exogenous genes, such as a neomycin resistance (Neo^R^) cassette. KO models for each gene were established in both C57BL/6JBomTac (B6) and FVB/NTac (FVB) genetic backgrounds.

Materials and Methods
=====================

*In vitro* synthesis of TALENs, Cas9 mRNA, and sgRNAs
-----------------------------------------------------

RNAs for TALENs and CRISPR/Cas9 were prepared as described previously \[[@B5][@B21][@B27]\]. Briefly, TALEN and *Cas9* mRNAs were synthesized *in vitro* from linear DNA templates (ToolGen, Korea) via the mMESSAGE mMACHINE T7 Ultra kit (Invitrogen, USA) according to the manufacturer\'s instructions. DNA templates for sgRNAs were synthesized *in vitro* by PCR. The sgRNAs were produced from these templates using a MEGA-shortscript T7 kit (Invitrogen, USA) according to the manufacturer\'s instructions. The sgRNAs were diluted in RNase-free injection buffer (0.25 mM EDTA, 10 mM Tris at pH 7.4) and introduced into the cytoplasm of fertilized eggs by microinjection. TALEN target sites were as follows: TALEN \#1 for p16, 5′-TGCATGACGT GCGGGCACTG-3′; TALEN \#2 for p16, 5′-TTCGGGG CGTTGGGCGAAAC-3′ for both B6 and FVB mice; TALEN \#1 of p19, 5′-TTCGTGCGATCCCGGAGACC-3′; TALEN \#2 of p19, 5′-TCACGAAAGCCAGAGCGC AG-3′ for both B6 and FVB mice. The following sequences were used for sgRNA synthesis: sgRNA \#1 of p27, 5′-GCGGATGGACGCCAGACAAG-3′; sgRNA \#2 of p27, 5′-GGACTTGGAGAAGCACTGCC-3′.

Generation and maintenance of p16, p19, and p27 KO mice
-------------------------------------------------------

*p16^Ink4a^*, *p19^Arf^*, and *p27^Kip1^* KO mice were established using engineered nucleases as described previously \[[@B21]\]. Briefly, TALENs or Cas9/sgRNAs were microinjected into the fertilized embryos of B6 and FVB mice. Mutations in the target genes were confirmed by Sanger sequencing (BIONICS, Korea). Mice were maintained on a normal chow diet under a twelve-hour (8:00--20:00 light) light/dark cycle at the specific-pathogen-free facility. All animal experiments were held in accordance with Korean Food and Drug Administration guidelines, and protocols were approved by the Institutional Animal Care and Use Committee of the Yonsei University (201507-390-01).

Genotyping of KO mice
---------------------

Mouse genotypes were confirmed by PCR using the following primers: 5′-GTTTAATGGGTGGCTCCGGT-3′ (p16-B6-KO-F), 5′-TTGGGCGAAACCCCAGC-3′ (p16-B6-KO-R) resulting 443 bps, 5′-CGTGCGGGCACTGCTGGAAGCCGG-3′ (p16-B6-WT-F), 5′-GGTGTTAGCGTGGGTAGCAG-3′ (p16-B6-WT-R) resulting 198 bps, 5′-GAGGAGAGCCATCTGGAG-3′ (p16-FVB-F), 5′-CCTTGCCTACCTGAATCG-3′ (p16-FVB-R) resulting 158 bps for WT and 133 bps for KO; 5′-AGGGTTTTCTTGGTGAAGTTC-3′ (p19-B6-F), 5′-TCCTCTCTAGCCTCAACAAC-3′ (p19-B6-R) resulting 94 bps for WT and 72 bps for KO, 5′-GCTTCTCACCTCGCTTGTC-3′ (p19-FVB-F), 5′-GAGCGCAGCTCGCG-3′ (p19-FVB-R WT), and 5′-AGAGCGCAGCTCGCTG-3′ (p19-FVB-R KO) resulting 200 bps for both WT and KO specific; 5′-CGCTTTTGTTCGGTTTTGTT-3′ (p27-F), 5′-CTCTCCACCTCCTGCCAC-3′ (p27-R) resulting 180 bps for WT and 94 bps for KO. PCR was performed as described previously \[[@B19]\] at the following annealing temperatures: p16 KO, 56℃ for B6 and 58℃ for FVB; p19 KO, 60℃ for both B6 and FVB; p27 KO, 56℃ for B6 and 68℃ for FVB. Electrophoresis was conducted on 2--3% agarose gels and visualized with a Bio-Rad ChemiDoc system (Bio-Rad, USA).

Western blotting
----------------

Protein lysates were prepared as described previously \[[@B20]\]. Briefly, cell lysates were prepared in RIPA lysis buffer containing protease inhibitor cocktail. Antibodies raised against p16 (sc-377412, Santa Cruz Biotechnology, USA) and ACTIN (sc-58673, Santa Cruz Biotechnology, USA) were used for detection via Western blot.

Results
=======

Generation of p16^Ink4a^ and p19^Arf^ KO mice using TALENs
----------------------------------------------------------

*Cdkn2a* is a cell cycle regulating gene that encodes two different proteins, called p16^Ink4a^ and p19^Arf^, through exon 1 variants \[[@B26][@B33]\]. To establish the *p16^Ink4a^* KO mouse model in the FVB background, a pair of TALEN RNAs targeting exon 1 of *p16^Ink4a^* was synthesized and microinjected into the mouse embryos. An FVB-*p16^Ink4a^* KO mouse line possessing a 25 bp deletion downstream of the start codon ([Figure 1A](#F1){ref-type="fig"}) was selected via PCR-based screening and Sanger sequencing. The resulting mutant *p16^Ink4a^* gene is predicted to encode only 11 amino acids (AAs) downstream of the mutation site, due to a frameshift-induced premature termination codon (PTC). Including sequence upstream of the mutation site, the truncated protein is predicted to include 34 AAs, compared to 168 AAs in the WT p16^Ink4a^ protein. Importantly, the PTC in the mutated transcripts may cause nonsense-mediated mRNA decay (NMD), resulting in remarkable reduction of mutant mRNA levels \[[@B18]\]. The genotypes of *p16^Ink4a^* KO mice were confirmed by PCR, and its products were represented in 158 bp for WT and 133 bp for KO ([Figure 1C](#F1){ref-type="fig"}). The same strategy was applied to establish the B6-*p16^Ink4a^* KO in the C57BL/6 strain, which generated a mouse line harboring a seven-nucleotide deletion predicted to produce abnormal 16 AAs before a PTC ([Figure 1B](#F1){ref-type="fig"}), leading to NMD-mediated mRNA degradation or translation of a predicted 40 AA peptide. In contrast, the WT p16^Ink4a^ protein is 168 AA in length. The genotyping PCR products represented in 443 bp for WT and in 198 bp for KO mice ([Figure 1D](#F1){ref-type="fig"}). Immunoblot assays were conducted to examine p16^Ink4a^ protein levels in mouse embryonic fibroblasts (MEFs). Ablation of p16^Ink4a^ protein was detected in *p16^Ink4a^* KO MEFs in both FVB and B6 strains ([Figures 1E and F](#F1){ref-type="fig"}), indicating that TALEN-induced *p16^Ink4a^* mutations successfully eliminated gene expression.

To produce the *p19^Arf^* KO mouse model, a strategy similar to the *p16^Ink4a^* KOs was deployed. One and twenty-two bp deletion mutants were generated that may produce only seven and five aberrant AAs downstream of the mutation sites in FVB and B6 strains, respectively. The mutant transcripts may undergo NMD or generate peptides 43 AAs in length in FVB and 36 AAs in length in B6 ([Figures 2A and B](#F2){ref-type="fig"}). The genotypes were confirmed by genotyping PCR. In the case of FVB *p19^Arf^* KO mouse, the PCR product size for WT and KO were identical at 200 bp, therefore they were verified in different agarose gels. Whereas the genotyping PCR products in the B6 *p19^Arf^* KO mouse represented in 94 bp for WT and in 72 bp for KO ([Figures 2C and D](#F2){ref-type="fig"}). Notably, previous *p16^Ink4a^* and *p19^Arf^* KO mouse models were established by replacing the exon(s) with a Neo^R^-cassette in ES cells \[[@B26]\], whereas our *Cdkn2a* KO mice are Neo^R^-free.

Generation of B6 *p27^Kip1^* KO mice by CRISPR/Cas9 microinjection
------------------------------------------------------------------

To establish the mouse model for p27^Kip1^, two sgRNAs targeting the first exon of were designed using sgRNA design tools to maximize on-target and minimize off-target activity \[[@B7][@B8]\]. The sgRNAs were synthesized and microinjected with *Cas9* mRNA into the mouse embryos to cause mutations at the target sites ([Figure 3](#F3){ref-type="fig"}). Through PCR-based genotyping and Sanger sequencing, we selected a mutant line harboring an 86 bp deletion between the target sites ([Figure 3A](#F3){ref-type="fig"}), resulting in the probable translation of 18 abnormal peptides downstream of the deletion site, followed by a PTC. Compared to WT *p27^Kip1^*, which encodes 198 AAs, the *p27^Kip1^* KO in B6 strain is predicted to produce only 39 AAs, if not completely silenced via NMD. The genotyping PCR products represented in 180 bp for WT and 94 bp for KO ([Figure 3B](#F3){ref-type="fig"}). Although some reduced RNA was detected in the liver of *p27^Kip1^* KO mouse, the verified genetic alteration ensured that a functional protein will not be expressed ([Figure 3C](#F3){ref-type="fig"}).

Discussion
==========

The KO mouse models we established possess small deletions in the first exon of each gene, leading to frameshift-mediated PTCs in the open reading frame of the genes. In addition to premature truncation, the introduced mutations may cause NMD of mutant mRNAs. NMD is a mRNA quality control mechanism that monitors translation and degrades mutant mRNA harboring PTC \[[@B18]\]. Therefore, expression of the targeted CDK inhibitors should be considerably decreased in their respective KO mice. The KO mice in this study will be helpful for further studies in areas such as cellular senescence, tumorigenesis, cataracts, and co-orchestration with oncogenes and tumor suppressors \[[@B15][@B26]\], without potential interference from external genes (e.g. Neo^R^). The Neo^R^ marker has been shown to affect glycolysis rate, induce C-MYC (which is frequently overexpressed in primary tumors), and suppress various genes by acting as a transcriptional silencer \[[@B1][@B31]\]. To avoid adverse effects and biased phenotypes, we generated KO mice lacking this cassette. Collectively, these models will be useful tools for the study of diseases associated with CDK inhibitor deficiency. All of these newly established models are available from the Korean Ministry of Food & Drug Safety ([www.nifds.go.kr](www.nifds.go.kr)) to support biomedical research.
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![TALEN-mediated generation of a *p16^Ink4a^* knockout mouse model. (A and B) Representative views of the transcription activator-like effector nuclease (TALEN) targeting strategy for generation of *p16^Ink4a^* KO mice in both FVB (A) and B6 (B) strains. A schematic of the *Cdkn2a* locus with TALEN-binding nucleotides (blue) and the amino acid sequences (purple) of the WT (upper) and KO (lower) mice are shown. *p16^Ink4a^* exons are indicated with boxes and introns are indicated by lines. Red asterisks indicate stop codons. (C and D) Representative results of PCR genotyping for FVB (C) and C57BL/6 (D) strains of WT and *p16^Ink4a^* KO mice. +/+, WT; +/−, Heterozygote KO; −/−, Homozygote KO. (E and F) Western blot analyses for p16 in FVB (E) and B6 (F) mouse embryonic fibroblasts. +/+ indicates WT and −/− indicates the *p16^Ink4a^* KO.](lar-34-264-g001){#F1}

![TALEN-mediated generation of a *p19^Arf^* knockout mouse model. (A and B) Representative views of the transcription activator-like effector nuclease (TALEN) targeting strategy for generation of *p19^Arf^* KO mice in both FVB (A) and B6 (B) strains. A schematic of the *Cdkn2a* locus with TALEN-binding nucleotides (blue) and the amino acid sequences (purple) of the WT (upper) and KO (lower) mice are shown. *p19^Arf^* exons are indicated with boxes and introns are indicated by lines. Red asterisks indicate stop codons. (C and D) Representative results of PCR genotyping for FVB (C) and B6 (D) strains of WT and *p19^Arf^* KO mice. +/+, WT; +/−, Heterozygote KO; −/−, Homozygote KO.](lar-34-264-g002){#F2}

![CRISPR/Cas9-mediated generation of B6-*p27^Kip1^* knockout mouse model. (A) Representative view of the clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9) targeting strategy for generation of *p27^Kip1^* KO mouse. A schematic of the *Cdkn1b* locus with single guide RNA target nucleotides (blue) and the amino acid sequences (purple) of the wild-type (upper) and knockout (lower) mice are shown. Exons are indicated with boxes and introns are indicated by lines. Red asterisks indicate stop codons. The protospacer adjacent motif for Cas9 is indicated in red. (B) A representative result of PCR genotyping for B6 strain of WT and *p27^Kip1^* KO mouse. +/+, WT; +/−, Heterozygote KO. (C) Semi-quantitative PCR analysis for *p27* transcript in the liver of WT and *p27^Kip1^* KO mouse. +/+, WT; −/−, Homozygote *p27^Kip1^* KO.](lar-34-264-g003){#F3}
